In June 2015, we were honoured to be
selected by
Forbes Asia
as one of the
“Best Under a Billion” companies. Winning
this accolade attests to the success and
growth of the Group, which has grown at
a 28.8% revenue CAGR for the past two
years. Moving forward, we will continue to
be on track to expand our businesses by
tapping on developing markets in India,
Indonesia and the Philippines. We will also
widen our scope of products and services
by introducing new healthcare products
catering to the mother and child segment.
DEAR VALUED SHAREHOLDERS,
On behalf of our Board of Directors, I would like to express
my most sincere gratitude to all our stakeholders who have
given the Group their unwavering support and trust. With
this, I am pleased to give you a report of our performance
and progress for the financial year ended on June 30, 2015
(“FY2015”).
OVERALL PERFORMANCE OF THE GROUP IN FY2015
This year marks Cordlife’s 14th year as a consumer
healthcare company serving the needs of mother and
child since we started operations in Singapore in 2001. As
we evolve from a home-grown private cord blood bank to
become a consumer healthcare group in Asia, we remain
focused on creating value for all our shareholders and
improving the quality of life for mothers and their children
by offering accountable services and diversifying products.
We are pleased that the Group has successfully sustained
a year-on-year growth in FY2015, with a 17.3% increase in
the Group’s revenue to S$57.6 million and full year net profit
growing 5.7% to S$32.1 million. Excluding non-core and
one-off items, the Group’s profit before income tax from
operations was S$6.1 million for FY2015.
To realize our commitment in sharing the Group’s success
with our shareholders as we grow, we propose a final,
1-tier tax exempt dividend of 1.0 cent per share, payable
on November 6, 2015. This is on top of the interim dividend
of 1.0 cent per share that was distributed on April 2, 2015,
bringing the total dividend payout to 2.0 cents per share in
FY2015. The strong top-line growth and increase in client
deliveries in FY2015 represent the strongest validation
of our business strategies, which gives us confidence to
pursue further growth.
ABUNDANT OPPORTUNITIES FOR SUSTAINABLE
GROWTH
Through the years, Cordlife has grown into a pan-Asian
company with the largest market share of the private cord
blood banking industry in Singapore, Indonesia and the
Philippines. In Hong Kong and India, we are amongst the
top three players in the market.
Growth of our business was propelled by our continued
efforts to maintain leadership in our markets and by several
positive catalysts such as favourable healthcare trends in
each country, as well as new beneficial policies recently
announced by the Singapore government.
8
CORDLIFE GROUP LIMITED
| ANNUAL REPORT 2015
CHAIRMAN’S
MESSAGE
